Cingulate Inc. (NASDAQ:CING – Free Report) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Cingulate in a research note issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.56) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Cingulate’s FY2026 earnings at ($2.13) EPS.
CING has been the subject of a number of other research reports. Wall Street Zen cut Cingulate from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Roth Mkm reiterated a “buy” rating and set a $10.00 target price on shares of Cingulate in a report on Tuesday, May 19th. Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Finally, Ascendiant Capital Markets reduced their price target on Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cingulate has an average rating of “Moderate Buy” and a consensus target price of $28.33.
Cingulate Stock Performance
Shares of NASDAQ:CING opened at $4.78 on Wednesday. Cingulate has a 1 year low of $3.20 and a 1 year high of $11.89. The stock has a market capitalization of $64.39 million, a P/E ratio of -1.13 and a beta of -0.81. The stock has a 50-day simple moving average of $5.79 and a 200-day simple moving average of $5.34.
Cingulate (NASDAQ:CING – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42).
Hedge Funds Weigh In On Cingulate
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC lifted its position in Cingulate by 29.8% during the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock worth $529,000 after acquiring an additional 27,979 shares in the last quarter. Geode Capital Management LLC lifted its position in Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after acquiring an additional 18,629 shares in the last quarter. DRW Securities LLC acquired a new position in Cingulate during the 4th quarter worth approximately $255,000. XTX Topco Ltd acquired a new position in Cingulate during the 4th quarter worth approximately $90,000. Finally, Quadrature Capital Ltd acquired a new position in Cingulate during the 4th quarter worth approximately $66,000. 41.31% of the stock is owned by institutional investors and hedge funds.
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Recommended Stories
- Five stocks we like better than Cingulate
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
